Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study
Authors:
- 22 July 2022
- journal article
- research article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 81 (11) , 1594-1602
Abstract
Objectives To evaluate long-term kinetics of the BNT162b2 mRNA vaccine-induced immune response in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) and immunocompetent controls. Methods A prospective multicentre study investigated serum anti-SARS-CoV-2 S1/S2 IgG titre at 2–6 weeks (AIIRD n=720, controls n=122) and 6 months (AIIRD n=628, controls n=116) after the second vaccine, and 2–6 weeks after the third vaccine dose (AIIRD n=169, controls n=45). T-cell immune response to the third vaccine was evaluated in a small sample. Results The two-dose vaccine regimen induced a higher humoral response in controls compared with patients, postvaccination seropositivity rates of 100% versus 84.72%, pConclusions The two-dose BNTb262 regimen was associated with similar clinical efficacy and similar waning of the humoral response over 6 months among patients with AIIRD and controls. The third vaccine dose restored the humoral response in all of the controls and the majority of patients.Keywords
This publication has 26 references indexed in Scilit:
- Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case seriesAnnals of the Rheumatic Diseases, 2022
- Covid-19 Breakthrough Infections in Vaccinated Health Care WorkersNew England Journal of Medicine, 2021
- Protection of BNT162b2 Vaccine Booster against Covid-19 in IsraelNew England Journal of Medicine, 2021
- SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunityAnnals of the Rheumatic Diseases, 2021
- Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre studyAnnals of the Rheumatic Diseases, 2021
- Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escapeNature Reviews Immunology, 2021
- Spike-antibody waning after second dose of BNT162b2 or ChAdOx1The Lancet, 2021
- Evidence for antibody as a protective correlate for COVID-19 vaccinesVaccine, 2021
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNature Medicine, 2021
- Weak correlation between antibody titers and neutralizing activity in sera from SARS‐CoV‐2 infected subjectsJournal of Medical Virology, 2020